Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma
“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” said Resolian CEO Patrick Bennett. “Denali’s founders and core scientists are internationally recognized across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services. We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”
“The Denali team is thrilled to join Resolian,” said Denali CEO Min Meng, Ph.D. “Denali was founded by a group of U.S.-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”
Share this:
Related Articles
U.S. Alliance Pharma Acquires UK-based LGC’s Drug Development Solutions Business (DDS)
Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions Business (DDS), a UK-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.
Alliance Pharma agrees to acquire LGC’s Drug Development Solutions Business Unit
Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will become an equal shareholder in the combined business alongside Ampersand Capital Partners. Backed by Ampersand and KKR, Alliance and DDS plan to expand the company’s geographic reach, broaden its laboratory capabilities and expand its service portfolio. The transaction is subject to regulatory approvals and expected to be completed in Q2 2022.
U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia
Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions Business (DDS), a UK-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.